- Home
- IMUX vs UFI Comparison
IMUX vs UFI Comparison
Compare IMUX & UFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- UFI
- Stock Information
- Founded
- IMUX 2016
- UFI 1969
- Country
- IMUX United States
- UFI United States
- Employees
- IMUX N/A
- UFI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- UFI Textiles
- Sector
- IMUX Health Care
- UFI Consumer Discretionary
- Exchange
- IMUX Nasdaq
- UFI Nasdaq
- Market Cap
- IMUX 90.3M
- UFI 85.7M
- IPO Year
- IMUX N/A
- UFI N/A
- Fundamental
- Price
- IMUX $0.98
- UFI $5.30
- Analyst Decision
- IMUX Strong Buy
- UFI
- Analyst Count
- IMUX 6
- UFI 0
- Target Price
- IMUX $13.20
- UFI N/A
- AVG Volume (30 Days)
- IMUX 661.4K
- UFI 68.7K
- Earning Date
- IMUX 05-07-2025
- UFI 05-07-2025
- Dividend Yield
- IMUX N/A
- UFI N/A
- EPS Growth
- IMUX N/A
- UFI N/A
- EPS
- IMUX N/A
- UFI N/A
- Revenue
- IMUX N/A
- UFI $592,700,000.00
- Revenue This Year
- IMUX N/A
- UFI $1.03
- Revenue Next Year
- IMUX N/A
- UFI $18.80
- P/E Ratio
- IMUX N/A
- UFI N/A
- Revenue Growth
- IMUX N/A
- UFI 1.57
- 52 Week Low
- IMUX $0.83
- UFI $4.25
- 52 Week High
- IMUX $2.11
- UFI $7.91
- Technical
- Relative Strength Index (RSI)
- IMUX 45.24
- UFI 59.22
- Support Level
- IMUX $0.86
- UFI $4.57
- Resistance Level
- IMUX $1.01
- UFI $4.92
- Average True Range (ATR)
- IMUX 0.09
- UFI 0.27
- MACD
- IMUX -0.01
- UFI 0.07
- Stochastic Oscillator
- IMUX 42.53
- UFI 73.43
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About UFI Unifi Inc. New
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.